Real-World Evidence (RWE) Data
Buy and sell real-world evidence (rwe) data data. Post-market outcomes, off-label usage, long-term safety — RWE fills the gap between trials and clinical reality.
No listings currently in the marketplace for Real-World Evidence (RWE) Data.
Find Me This Data →Overview
What Is Real-World Evidence (RWE) Data?
Real-World Evidence (RWE) data comprises information on patient health outcomes and healthcare delivery collected routinely from diverse sources—electronic health records, medical device registries, administrative claims, biobanks, and public health surveillance systems. RWE fills a critical gap between controlled clinical trials and actual clinical practice by capturing long-term safety profiles, off-label usage patterns, and effectiveness across diverse patient populations that traditional randomized controlled trials often exclude due to strict inclusion/exclusion criteria. RWE has gained regulatory traction across pharmaceutical and medical device approval processes. Regulatory authorities increasingly accept RWE as valid scientific evidence for new claims, indications, and post-market surveillance. Advanced methodologies now include registry-claims data linkage, propensity score adjustment, hybrid trial designs integrating prospective clinical data with real-world registry information, and generation of external controls from administrative and registry data to support single-arm studies.
Market Data
$2.0 billion
Global RWE Solutions Market Size (2024)
Source: MarketsandMarkets
$4.5 billion
Projected Market Size (2029)
Source: MarketsandMarkets
16.5% CAGR
Market Growth Rate (2024–2029)
Source: MarketsandMarkets
73 market authorizations
FDA RWE Examples in Medical Device Decisions (FY 2020–2025)
Source: FDA
Largest regional share
North America Market Share (2023)
Source: MarketsandMarkets
Who Uses This Data
What AI models do with it.do with it.
Pharmaceutical Companies
Support applications for new drug claims and indications; conduct post-market surveillance to understand real-world drug performance beyond trial settings and identify long-term safety signals.
Medical Device Manufacturers
Enable regulatory submissions using device-generated data, medical records, and registries; support premarket clearance decisions and post-approval study requirements through diverse RWD sources.
Healthcare Payers & Insurance Organizations
Use RWE solutions to assess treatment effectiveness and healthcare utilization; inform coverage and reimbursement decisions based on real-world clinical outcomes and value-based pricing models.
Regulatory Agencies & Health Systems
Leverage RWE for device approval decisions, validate clinical data, and conduct public health surveillance to monitor safety and efficacy across diverse populations.
What Can You Earn?
What it's worth.worth.
Clinical Data Sets
Varies
Sourced from EHRs, registries, and biobanks; pricing depends on granularity, population size, and follow-up duration.
Claims & Administrative Data
Varies
Comprehensive healthcare utilization and outcomes data; value driven by sample size and completeness of long-term follow-up records.
Device-Generated Data
Varies
Real-time patient monitoring and device performance data; emerging data source with growing demand for post-market surveillance.
Registry & Integrated Data
Varies
Linked registry-claims datasets enabling sophisticated post-market surveillance; premium pricing for multi-source integration and advanced methodologies.
What Buyers Expect
What makes it valuable.valuable.
Robust Study Protocol & Statistical Plan
RWE datasets must be supported by rigorous hypothesis-driven protocols and statistical analysis plans that address differences in population characteristics and data collection methods to ensure data integrity and comparability to clinical trial standards.
Diverse & Representative Populations
Buyers require larger sample sizes with variability across demographic groups, treatment patterns, and comorbidities—capturing real-world heterogeneity that randomized controlled trials exclude through strict eligibility criteria.
Long-Term & Comprehensive Follow-Up
Data must include sustained post-market surveillance outcomes, safety signals, and effectiveness assessments beyond traditional trial follow-up periods, often integrated across multiple registry and claims sources.
Advanced Data Quality & Integration
Sophisticated linkages between registries, claims data, electronic health records, and biobanks; use of propensity score and other advanced statistical techniques to minimize confounding and selection bias.
Companies Active Here
Who's buying.buying.
Global RWE solutions provider supporting pharmaceutical and device companies with clinical data, claims analytics, and regulatory submissions.
Healthcare data and RWE services leveraging administrative claims and health records for payer and manufacturer decision-making.
Enterprise healthcare data platforms enabling integration and analysis of RWD across registries, EHRs, and claims systems.
FAQ
Common questions.questions.
How does RWE differ from traditional clinical trial data?
RWE captures patient outcomes in real-world clinical settings with diverse, heterogeneous populations and longer follow-up periods, whereas randomized controlled trials use homogeneous populations with strict inclusion/exclusion criteria. While RCTs provide robust causal evidence under controlled conditions, RWE demonstrates effectiveness and safety across broader populations and real-world treatment variability, often revealing off-label usage patterns and long-term safety signals not observed in trials.
What data sources qualify as RWE?
RWE sources include electronic health records (EHRs), medical device registries, administrative claims data, device-generated data, clinically annotated biobanks, public health surveillance systems, medical device data repositories, and chargemaster/billing data. FDA guidance recognizes increasingly diverse and integrated RWD sources, including linked registry-claims datasets and hybrid designs combining prospective clinical trial data with real-world registry information.
How is RWE used in regulatory decisions?
Regulatory authorities accept RWE as valid scientific evidence to support new drug claims, device indications, and premarket submissions. RWE also supports post-approval study requirements and long-term post-market surveillance. Advanced methodologies include propensity score analysis to control confounding, generation of external controls from registry and claims data for single-arm studies, and sophisticated data integration approaches that strengthen evidentiary basis for regulatory decision-making.
What is the current market opportunity for RWE data?
The global RWE Solutions market was valued at $2.0 billion in 2024 and is projected to grow at 16.5% CAGR to $4.5 billion by 2029. North America dominates due to favorable regulatory environment, widespread EHR adoption, and presence of major players like IQVIA, Optum, and Oracle. Growth is driven by increasing adoption by payers, pharmaceutical and device manufacturers, and regulatory agencies seeking robust real-world evidence for decision-making.
Sell yourreal-world evidence (rwe)data.
If your company generates real-world evidence (rwe) data, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation